Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex’s monopoly.
But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
Annexon becomes the latest group to provide a confusing update in the disease.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.